Recent advances in the development of immunotherapies for tauopathies.
The use of immunotherapy for Alzheimer's disease (AD) has traditionally focused on the amyloid-β (Aβ) peptide and has shown great potential in both animal and human studies. However, an emerging body of work has begun to concentrate on tau and to develop immunization protocols designed to decrease tau pathology in AD and other tauopathies. This commentary will discuss the use of immunotherapy for AD, focusing on tau immunotherapy in the context of recent reports on the use of tau phospho-peptides in transgenic models of tau pathology.
Ubhi
Kiren
K
Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA. emasliah@ucsd.edu
Masliah
Eliezer
E
D000544:Alzheimer Disease / Q000628:therapy; D000818:Animals; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D024801:Tauopathies / Q000628:therapy*